Presentations at CICON on Friday, Sep. 27, at 1:00 PM and 6:30 PM CEST and at ESMO on Saturday, Sep. 28, at 12:00 PM CEST AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 & 3, ...

CD8+ T cells responding to persistent antigenic stimulation, for example during chronic viral infections and cancer, undergo a process named T-cell exhaustion. Exhausted T cells are heterogeneous, ...

Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis NEW YORK & MONTREAL--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: ...

In a recent study posted to the medRxiv* pre-print server, a team of researchers demonstrated the inhibitory action of integrin/transforming growth factor beta 1 (TGF-β1) inhibitor GLPG0187 on severe ...

Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. This is an ASCO Meeting Abstract ...

Randomized phase III trial of FOLFOX versus XELOX as adjuvant chemotherapy in patients with early-stage colorectal adenocarcinoma. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I.

DUBLIN – The contest to develop new therapeutics targeting transforming growth factor beta 1 (TGF-beta1) signaling in cancer intensified this week, as both Abbvie Inc. and Scholar Rock Holding Corp.

AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive ...

Researchers at University of California San Diego have found that the most common form of liver cancer - one with a high mortality rate - can be better targeted and treated using an innovative new ...

Barcelona, Wed. Feb. 14, 2018.- In a short space of time, immunotherapy, that is to say therapies based on stimulating the immune system against cancer cells, has become a powerful approach to treat ...